Pharma Industrial India Magazine - July - August 2024

PHARMA INDUSTRIALINDIA · JUL-AUG 24 13 INTERVIEW turing. Thus, TechInvention advice its cli- ents on establishing procedures based on the above-mentioned guidelines. Normally setting up and operating cGMP complaint facilities require high CAPEX and OPEX which becomes a challenge in Low- and Middle-Income Countries (LMIC) and Low-Income Countries (LIC) settings. Secondly getting or sourcing adequately skilled and qualified human resource remains a perennial issue in such settings. Besides the above, rick- ety legal and Intellectual Property (IP) framework discourages international research institutes, vaccines manufac- turers and organizations venture into partnerships and associations for co-de- velopment and technology transfers. Q What are the future trends in vac- cine manufacturing that TechInven- tion is preparing for? Syed Ahmed: We have established vac- cine platform technologies for recombi- nant protein, conjugate and are working towards OMV-based and mRNA vac- cines. TechInvention’s upcoming state of the art facility, Global Collaborative Center for Medical Countermeasures (GCMC) initiative will enable comprehensive bio- logics development from strain to supply under a single roof thus erasing the need for multiple partnerships. Our focus includes developing vac- cines for diseases endemic to low- and middle-income countries (LMICs) and fostering public-private partnerships to speed up vaccine development and dis- tribution. We’re also committed to sus- tainable practices, including reducing waste and energy use, and implement- ing green technologies like solar panels and rainwater harvesting. Ensuring equitable global vaccine ac- cess, especially in LMICs, is a priority. TechInvention offers consulting services from project feasibility to commercial- ization, aiming to enhance vaccine de- velopment efficiency and global public health resilience. Q How does TechInvention address the challenges of cold chain man- agement in vaccine distribution? Syed Ahmed: Our team and logistics personnel are well-versed in best prac- tices for maintaining cold chain integrity, complying with WHO guidelines (ANNEX 9, ANNEX 3 TRS NO 962, ANNEX 3, AN- NEX 5, TRS NO 999). We collaborate with leading logistics providers special- izing in cold chain management, ensur- ing vaccines are handled and transport- ed under the strictest conditions from manufacturing facilities to the final point of administration. In an advisory capacity we advocate es- tablishing local manufacturing and distri- bution hubs in strategic regions, thereby reducing the distance vaccines need to travel, minimizing the risk of temperature excursions and ensuring faster delivery times. Additionally, we are developing inno- vative technologies to create thermo- stable vaccines using excipients t o reduce the cold chain burden. Q What are the long-term strategic goals for TechInvention in the phar- maceutical industry? Syed Ahmed: TechInvention is commit- ted to advancing vaccine technologies by continually developing and enhanc- ing cutting-edge platforms, including recombinant protein, conjugate, OMV- based, and mRNA vaccines. These ef- forts aim to address both current and emerging infectious diseases. We are actively consulting on various vaccine manufacturing projects world- wide, with the goal of establishing local manufacturing and distribution hubs in strategic regions. This ensures time- ly access to high-quality vaccines and pharmaceutical products, particularly in low- and middle-income countries (LMICs). Promoting sustainable practices is a core objective. We guide our project partners in reducing waste, energy consump- tion, and environmental impact, creating eco-friendly production systems that contribute to global sustainability in the pharmaceutical industry. Given the rise of zoonotic infections and the threat of future pandemics, we are investing heavily in R&D to discover and develop novel therapeutics and vac- cines. Our focus is on addressing unmet medical needs and emerging health threats, leveraging advanced technolo- gies and scientific expertise. The state-of-the-art facility being con- structed at a strategic location in Mum- bai will serve as a one-stop solution for vaccines, biotherapeutics, and diagnos- tics in the arena of infectious diseases, aiming to combat the global burden and improve lives.